$470 Million Acquisition Signals Fierce Race in Alzheimer’s Drug Development

Sanofi has struck a $470 million deal to acquire Vigil Neuroscience, a bold move aimed at securing VG-3927, an investigational oral small molecule designed to target TREM2—a key immune receptor linked to Alzheimer’s disease. This acquisition, expected to close in Q3 2025, also includes a $2 contingent value right (CVR) per share tied to VG-3927’s first commercial sale.

VG-3927, which enables once-daily dosing, is on track to enter Phase II clinical trials later this year. Earlier Phase I data revealed a dose-dependent drop of up to 50% in soluble TREM2 levels in cerebrospinal fluid, signaling promising biological activity.

As competition heats up, giants like Pfizer, AbbVie, Eisai, and Eli Lilly are advancing amyloid-targeted therapies already approved by the FDA, including Lecanemab and Donanemab. At the same time, companies such as Bristol Myers Squibb, Roche, and Sanofi are bolstering their neuro pipelines through aggressive M&A activity.

In parallel, BioArctic recently secured a $1 billion+ licensing deal with BMS for next-gen amyloid antibodies using BrainTransporter™ tech, while AbbVie’s acquisition of Aliada focuses on BBB-penetrating therapies like ALIA-1758. Genentech, under Roche, is also advancing gene-silencing therapies targeting Tau via zinc finger technology.

Despite massive investment, Alzheimer’s remains a high-risk arena. Between 1998 and 2017, 146 out of 150 drug programs failed, underscoring the field’s complexity. Most recently, AstraZeneca exited several neuroscience programs, including its Alzheimer’s collaboration with Lilly, highlighting the volatile nature of the sector.